Compare Microsoft (MSFT) vs Novo Nordisk A/S (NVO) Price & Performance

MicrosoftTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Microsoft vs Novo Nordisk A/S — how do they compare? Microsoft trades at $396.4 (market cap $2.99T), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Microsoft is far larger — about 13.6× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	MSFT	NVO
Market Cap	$2.99T	$220.53B
Volume	36,654,621	—
Sector	Technology	Health
52-Week High	$542.07	$71.70
52-Week Low	$352.83	$35.29
Enterprise Value	$2.97T	$239.49B
Dividend Yield	0.9%	3.63%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Microsoft

Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.

The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.

Novo Nordisk A/S

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSFT

Roundhill Magnificent Seven ETF offers equal exposure to top 7 mega-cap tech stocks but with higher risk and cost.24/7 Wall Street · 6 hours agoNeutral Microsoft shifts to AI-driven revenue model amid record $190B capex and strong demand.Seeking Alpha · 7 hours agoBullish OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 9 hours agoNeutral View details →

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 10 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 14 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.